| Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis OJ Adedokun, WJ Sandborn, BG Feagan, P Rutgeerts, Z Xu, CW Marano, ... Gastroenterology 147 (6), 1296-1307. e5, 2014 | 354 | 2014 |
| Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis AA Fasanmade, OJ Adedokun, J Ford, D Hernandez, J Johanns, C Hu, ... European journal of clinical pharmacology 65, 1211-1228, 2009 | 345 | 2009 |
| Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials AA Fasanmade, OJ Adedokun, M Blank, H Zhou, HM Davis Clinical therapeutics 33 (7), 946-964, 2011 | 315 | 2011 |
| Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α DJ Shealy, A Cai, K Staquet, A Baker, ER Lacy, L Johns, O Vafa, G Gunn, ... MAbs 2 (4), 428-439, 2010 | 294 | 2010 |
| Pharmacokinetics and safety of golimumab, a fully human anti‐TNF‐α monoclonal antibody, in subjects with rheumatoid arthritis H Zhou, H Jang, RM Fleischmann, E Bouman‐Thio, Z Xu, JC Marini, ... The Journal of Clinical Pharmacology 47 (3), 383-396, 2007 | 225 | 2007 |
| Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL‐12/23p40, in patients with moderate to severe plaque psoriasis Y Zhu, C Hu, M Lu, S Liao, JC Marini, J Yohrling, N Yeilding, HM Davis, ... The Journal of Clinical Pharmacology 49 (2), 162-175, 2009 | 172 | 2009 |
| Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab JM Benson, CW Sachs, G Treacy, H Zhou, CE Pendley, CM Brodmerkel, ... Nature biotechnology 29 (7), 615-624, 2011 | 167 | 2011 |
| Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein H Zhou The Journal of Clinical Pharmacology 45 (5), 490-497, 2005 | 157 | 2005 |
| Pharmacokinetic strategies in deciphering atypical drug absorption profiles H Zhou The Journal of Clinical Pharmacology 43 (3), 211-227, 2003 | 152 | 2003 |
| Characterizing the impact of renal impairment on the clinical pharmacology of biologics B Meibohm, H Zhou The Journal of Clinical Pharmacology 52 (S1), 54S-62S, 2012 | 139 | 2012 |
| Population pharmacokinetics of infliximab in patients with ankylosing spondylitis Z Xu, K Seitz, A Fasanmade, J Ford, P Williamson, W Xu, HM Davis, ... The Journal of Clinical Pharmacology 48 (6), 681-695, 2008 | 137 | 2008 |
| Interspecies scaling of therapeutic monoclonal antibodies: initial look J Ling, H Zhou, Q Jiao, HM Davis The Journal of Clinical Pharmacology 49 (12), 1382-1402, 2009 | 134 | 2009 |
| Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development MA Mascelli, H Zhou, R Sweet, J Getsy, HM Davis, M Graham, ... The Journal of Clinical Pharmacology 47 (5), 553-565, 2007 | 122 | 2007 |
| Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and … OJ Adedokun, Z Xu, CW Marano, R Strauss, H Zhang, J Johanns, H Zhou, ... Journal of Crohn's and Colitis 11 (1), 35-46, 2017 | 121 | 2017 |
| Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study Z Xu, E Bouman‐Thio, C Comisar, B Frederick, B Van Hartingsveldt, ... British journal of clinical pharmacology 72 (2), 270-281, 2011 | 115 | 2011 |
| Population pharmacokinetics of golimumab, an anti‐tumor necrosis factor‐α human monoclonal antibody, in patients with psoriatic arthritis Z Xu, T Vu, H Lee, C Hu, J Ling, H Yan, D Baker, A Beutler, C Pendley, ... The Journal of Clinical Pharmacology 49 (9), 1056-1070, 2009 | 112 | 2009 |
| “Cocktail” approaches and strategies in drug development: valuable tool or flawed science? H Zhou, Z Tong, JF McLeod The Journal of Clinical Pharmacology 44 (2), 120-134, 2004 | 108 | 2004 |
| Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives–an update N Yeilding, P Szapary, C Brodmerkel, J Benson, M Plotnick, H Zhou, ... Annals of the New York Academy of Sciences 1263 (1), 1-12, 2012 | 104 | 2012 |
| Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects Z Xu, Q Wang, Y Zhuang, B Frederick, H Yan, E Bouman‐Thio, JC Marini, ... The Journal of Clinical Pharmacology 50 (3), 276-284, 2010 | 101 | 2010 |
| Population pharmacokinetic analysis and simulation of the time‐concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis DS Yim, H Zhou, M Buckwalter, I Nestorov, CC Peck, H Lee The Journal of Clinical Pharmacology 45 (3), 246-256, 2005 | 97 | 2005 |
